Pharmaceuticals, Biotechnology and Life Sciences
Oxford BioDynamics (OBD) has entered into a pilot development agreement with EpiFit PTE. LTD., (EpiFit), a new Singapore based company, to identify epigenetic biomarkers to evaluate predispositions, variations and responses in healthy volunteers undergoing fitness programmes conducted by EpiFit.
Consort Medical, a single source drug and delivery device company, has participated in a further equity raise by Atlas Genetics Ltd.
Cellectis’s scinetists lead by Dr Alexandre Juillerat have designed a new CAR architecture that contains an integrated microenvironment sensor. Their work was recently published in a scientific magazine “Scientific Reports”.
Mereo BioPharma said on Monday that all three of its submitted abstracts have been accepted for presentation as posters at the American Thoracic Society meeting in Washington, 19-24 May 2017.
Xintela AB has reported positive results in its two main projects in regenerative medicine and cancer.
Flu, or influenza, is a very contagious, acute, viral respiratory infection. Influenza viruses vary in a high degree. The extent…
For the last year, Sanofi’s chief executive has made clear his quest for deals to help revive the fortunes of France’s biggest drugmaker.
The market is still waiting. Olivier Brandicourt’s failure to land two big biotech acquisitions he was chasing has led to growing impatience among some investors.
Abzena has made a deal with a San Diego-based biopharmaceutical company for Abzena’s novel site–specific ThioBridge antibody drug conjugate (ADC) linker technology, which links antibodies and other proteins to drugs. The $300 million worth agreement with the…
French company Cerenis Therapeutics has seen some good things happen in the previous period in clinics by finalizing certain studies and getting FDA’s approval to kick some off. Also certain results showed progress and the company has reported solid cash position for the end of the year.
Japanese Ministry of Health, Labour and Welfare (MHLW) has granted priority review to Bayer Yakuhin for regorafenib in the second-line…